 Amrut Ambardekar
Concepts (432)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 38 | 2025 | 557 | 8.060 |
Why?
| | Heart Failure | 53 | 2025 | 2067 | 6.240 |
Why?
| | Heart Transplantation | 24 | 2024 | 709 | 4.670 |
Why?
| | Cardiomyopathies | 10 | 2025 | 325 | 1.870 |
Why?
| | Amyloidosis | 4 | 2023 | 48 | 1.740 |
Why?
| | Heart Ventricles | 9 | 2020 | 746 | 1.560 |
Why?
| | Cardiomyopathy, Dilated | 9 | 2020 | 334 | 1.090 |
Why?
| | Ventricular Dysfunction, Left | 8 | 2023 | 365 | 1.040 |
Why?
| | Myocytes, Cardiac | 13 | 2025 | 513 | 1.010 |
Why?
| | Cardiomyopathy, Hypertrophic | 2 | 2024 | 140 | 0.940 |
Why?
| | Myocardium | 10 | 2023 | 921 | 0.920 |
Why?
| | Arrhythmias, Cardiac | 6 | 2022 | 329 | 0.830 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2020 | 239 | 0.800 |
Why?
| | Humans | 104 | 2025 | 138651 | 0.800 |
Why?
| | Defibrillators, Implantable | 4 | 2020 | 306 | 0.790 |
Why?
| | Rejuvenation | 1 | 2022 | 19 | 0.760 |
Why?
| | Assisted Circulation | 2 | 2021 | 25 | 0.740 |
Why?
| | Aortic Valve Insufficiency | 1 | 2022 | 44 | 0.730 |
Why?
| | Transplant Recipients | 4 | 2021 | 173 | 0.730 |
Why?
| | Fibrosis | 5 | 2022 | 539 | 0.720 |
Why?
| | Echocardiography | 7 | 2017 | 640 | 0.720 |
Why?
| | Vascular Stiffness | 2 | 2017 | 443 | 0.710 |
Why?
| | Stroke Volume | 9 | 2024 | 584 | 0.710 |
Why?
| | Hemodynamics | 7 | 2023 | 1093 | 0.700 |
Why?
| | Amyloid Neuropathies, Familial | 3 | 2025 | 16 | 0.690 |
Why?
| | Calcineurin Inhibitors | 1 | 2021 | 70 | 0.680 |
Why?
| | Giant Cells | 1 | 2020 | 23 | 0.670 |
Why?
| | Arteries | 1 | 2022 | 263 | 0.660 |
Why?
| | Aortic Diseases | 1 | 2021 | 119 | 0.650 |
Why?
| | Ventricular Function, Left | 7 | 2023 | 502 | 0.650 |
Why?
| | Immunosuppressive Agents | 5 | 2021 | 849 | 0.650 |
Why?
| | Heart Neoplasms | 1 | 2020 | 56 | 0.640 |
Why?
| | Sarcoma, Kaposi | 1 | 2020 | 79 | 0.640 |
Why?
| | Myocarditis | 1 | 2020 | 100 | 0.610 |
Why?
| | Coronary Vessels | 2 | 2018 | 247 | 0.610 |
Why?
| | Ventricular Function, Right | 4 | 2020 | 279 | 0.600 |
Why?
| | Graft Rejection | 3 | 2021 | 536 | 0.590 |
Why?
| | Middle Aged | 37 | 2025 | 33604 | 0.590 |
Why?
| | Myocardial Contraction | 4 | 2020 | 303 | 0.580 |
Why?
| | Brugada Syndrome | 2 | 2009 | 14 | 0.570 |
Why?
| | Ventricular Remodeling | 4 | 2025 | 257 | 0.560 |
Why?
| | Heart | 6 | 2023 | 611 | 0.560 |
Why?
| | Male | 51 | 2025 | 68260 | 0.540 |
Why?
| | Bariatric Surgery | 1 | 2021 | 217 | 0.530 |
Why?
| | Extracellular Matrix | 1 | 2021 | 541 | 0.530 |
Why?
| | Myocardial Ischemia | 4 | 2019 | 278 | 0.510 |
Why?
| | Female | 49 | 2025 | 73763 | 0.480 |
Why?
| | Cryosurgery | 1 | 2016 | 46 | 0.480 |
Why?
| | Heart Rate | 2 | 2021 | 802 | 0.460 |
Why?
| | Thrombosis | 2 | 2016 | 374 | 0.460 |
Why?
| | Aged | 23 | 2025 | 24024 | 0.430 |
Why?
| | Tachycardia, Ventricular | 1 | 2016 | 175 | 0.430 |
Why?
| | Surgical Procedures, Operative | 1 | 2017 | 266 | 0.430 |
Why?
| | Blood Pressure | 5 | 2022 | 1739 | 0.430 |
Why?
| | Electrocardiography | 4 | 2020 | 612 | 0.410 |
Why?
| | Marijuana Abuse | 1 | 2016 | 226 | 0.410 |
Why?
| | Aorta, Thoracic | 1 | 2015 | 276 | 0.390 |
Why?
| | Treatment Outcome | 13 | 2024 | 10923 | 0.390 |
Why?
| | Prealbumin | 4 | 2025 | 30 | 0.390 |
Why?
| | Myofibrils | 3 | 2022 | 48 | 0.380 |
Why?
| | Physician-Patient Relations | 1 | 2017 | 581 | 0.380 |
Why?
| | Patient-Centered Care | 2 | 2021 | 539 | 0.370 |
Why?
| | Guideline Adherence | 3 | 2011 | 559 | 0.350 |
Why?
| | Adult | 21 | 2023 | 38201 | 0.330 |
Why?
| | Cardiology | 2 | 2023 | 279 | 0.330 |
Why?
| | Patient Compliance | 2 | 2017 | 598 | 0.330 |
Why?
| | Recovery of Function | 2 | 2011 | 665 | 0.320 |
Why?
| | Cardiac Tamponade | 1 | 2010 | 14 | 0.320 |
Why?
| | RNA, Long Noncoding | 2 | 2022 | 171 | 0.320 |
Why?
| | Calcium | 4 | 2023 | 1180 | 0.320 |
Why?
| | Risk Assessment | 6 | 2021 | 3433 | 0.310 |
Why?
| | Baroreflex | 2 | 2021 | 56 | 0.310 |
Why?
| | Sarcomeres | 3 | 2022 | 93 | 0.310 |
Why?
| | Hospitals, Rural | 1 | 2009 | 44 | 0.310 |
Why?
| | Cardiac Output | 3 | 2023 | 177 | 0.300 |
Why?
| | Safety | 1 | 2011 | 347 | 0.300 |
Why?
| | Electric Stimulation Therapy | 1 | 2010 | 81 | 0.300 |
Why?
| | Automobile Driving | 1 | 2011 | 150 | 0.300 |
Why?
| | Cardiac Pacing, Artificial | 1 | 2009 | 78 | 0.300 |
Why?
| | Hospitals, Urban | 1 | 2009 | 137 | 0.300 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2490 | 0.300 |
Why?
| | Cannabis | 1 | 2016 | 500 | 0.300 |
Why?
| | Pulsatile Flow | 2 | 2018 | 55 | 0.290 |
Why?
| | Registries | 6 | 2021 | 2073 | 0.290 |
Why?
| | Mastitis | 1 | 2007 | 5 | 0.280 |
Why?
| | Vascular Remodeling | 2 | 2021 | 192 | 0.280 |
Why?
| | Counseling | 1 | 2011 | 392 | 0.280 |
Why?
| | Mineralocorticoid Receptor Antagonists | 2 | 2023 | 55 | 0.270 |
Why?
| | Puerperal Disorders | 1 | 2007 | 31 | 0.270 |
Why?
| | Diagnosis, Differential | 4 | 2019 | 1482 | 0.270 |
Why?
| | Quality Assurance, Health Care | 1 | 2009 | 331 | 0.270 |
Why?
| | Coronary Disease | 1 | 2009 | 371 | 0.260 |
Why?
| | Length of Stay | 2 | 2009 | 1238 | 0.260 |
Why?
| | Environment | 1 | 2009 | 339 | 0.260 |
Why?
| | Prospective Studies | 10 | 2021 | 7554 | 0.250 |
Why?
| | Diastole | 2 | 2018 | 141 | 0.240 |
Why?
| | Follow-Up Studies | 6 | 2021 | 5112 | 0.240 |
Why?
| | Retrospective Studies | 13 | 2023 | 15909 | 0.240 |
Why?
| | HIV Infections | 1 | 2020 | 2941 | 0.230 |
Why?
| | Troponin I | 2 | 2019 | 81 | 0.230 |
Why?
| | Inpatients | 1 | 2009 | 502 | 0.230 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2025 | 34 | 0.230 |
Why?
| | Heart Failure, Systolic | 2 | 2024 | 25 | 0.220 |
Why?
| | Quality of Health Care | 1 | 2009 | 654 | 0.220 |
Why?
| | Methyltransferases | 1 | 2025 | 72 | 0.220 |
Why?
| | Quality of Life | 6 | 2024 | 2954 | 0.200 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2023 | 8 | 0.200 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2023 | 32 | 0.200 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2021 | 2113 | 0.200 |
Why?
| | Perioperative Care | 2 | 2017 | 213 | 0.200 |
Why?
| | MicroRNAs | 2 | 2022 | 675 | 0.190 |
Why?
| | Heart Injuries | 1 | 2023 | 40 | 0.190 |
Why?
| | Preoperative Care | 2 | 2017 | 367 | 0.190 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2022 | 43 | 0.190 |
Why?
| | Physical Conditioning, Animal | 1 | 2025 | 254 | 0.190 |
Why?
| | Patient Transfer | 2 | 2019 | 178 | 0.190 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2023 | 98 | 0.190 |
Why?
| | Metalloproteases | 1 | 2022 | 42 | 0.190 |
Why?
| | Cadherin Related Proteins | 1 | 2022 | 13 | 0.190 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 448 | 0.180 |
Why?
| | Cohort Studies | 6 | 2023 | 5697 | 0.180 |
Why?
| | Matrix Metalloproteinases, Secreted | 1 | 2021 | 12 | 0.180 |
Why?
| | Long Term Adverse Effects | 1 | 2021 | 12 | 0.180 |
Why?
| | ADAMTS4 Protein | 1 | 2021 | 15 | 0.180 |
Why?
| | Hospitalization | 4 | 2024 | 2235 | 0.180 |
Why?
| | Succinic Acid | 2 | 2019 | 41 | 0.180 |
Why?
| | Triage | 1 | 2024 | 241 | 0.180 |
Why?
| | Cation Transport Proteins | 1 | 2022 | 109 | 0.180 |
Why?
| | Leukopenia | 1 | 2021 | 31 | 0.180 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 20 | 0.180 |
Why?
| | Cardiovascular System | 1 | 2023 | 136 | 0.180 |
Why?
| | Calcium-Binding Proteins | 1 | 2022 | 215 | 0.170 |
Why?
| | Mice | 13 | 2025 | 17814 | 0.170 |
Why?
| | Prognosis | 5 | 2025 | 3984 | 0.170 |
Why?
| | Pressoreceptors | 1 | 2021 | 19 | 0.170 |
Why?
| | Carrier Proteins | 2 | 2022 | 737 | 0.170 |
Why?
| | Muscle Proteins | 1 | 2022 | 239 | 0.170 |
Why?
| | Hypertension | 2 | 2020 | 1242 | 0.170 |
Why?
| | Mycophenolic Acid | 1 | 2021 | 118 | 0.170 |
Why?
| | Case-Control Studies | 4 | 2022 | 3523 | 0.170 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 639 | 0.170 |
Why?
| | Alternative Splicing | 1 | 2022 | 227 | 0.160 |
Why?
| | Myocardial Infarction | 2 | 2023 | 1059 | 0.160 |
Why?
| | Transcriptome | 3 | 2025 | 967 | 0.160 |
Why?
| | Cell Adhesion | 2 | 2018 | 466 | 0.160 |
Why?
| | Immunohistochemistry | 2 | 2021 | 1731 | 0.160 |
Why?
| | Disease Progression | 2 | 2018 | 2749 | 0.150 |
Why?
| | HIV | 1 | 2020 | 246 | 0.150 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 285 | 0.150 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2851 | 0.150 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2020 | 147 | 0.150 |
Why?
| | Aortic Valve | 1 | 2022 | 358 | 0.150 |
Why?
| | Terminology as Topic | 1 | 2020 | 243 | 0.150 |
Why?
| | Consensus | 4 | 2023 | 685 | 0.150 |
Why?
| | Animals | 16 | 2025 | 37217 | 0.150 |
Why?
| | Cell Culture Techniques | 1 | 2021 | 364 | 0.140 |
Why?
| | United States | 9 | 2023 | 14938 | 0.140 |
Why?
| | Exercise Test | 4 | 2023 | 622 | 0.140 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2020 | 178 | 0.140 |
Why?
| | Longitudinal Studies | 3 | 2016 | 2844 | 0.140 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 245 | 0.140 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 334 | 0.140 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 248 | 0.140 |
Why?
| | Filamins | 1 | 2018 | 27 | 0.140 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 192 | 0.140 |
Why?
| | Mitochondrial Proteins | 1 | 2019 | 258 | 0.130 |
Why?
| | NAV1.5 Voltage-Gated Sodium Channel | 1 | 2017 | 14 | 0.130 |
Why?
| | Recurrence | 1 | 2020 | 1084 | 0.130 |
Why?
| | Mutation | 2 | 2018 | 3987 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2018 | 269 | 0.130 |
Why?
| | Caliciviridae Infections | 1 | 2016 | 20 | 0.130 |
Why?
| | Pilot Projects | 3 | 2019 | 1765 | 0.130 |
Why?
| | ErbB Receptors | 1 | 2020 | 609 | 0.130 |
Why?
| | PTEN Phosphohydrolase | 1 | 2018 | 163 | 0.130 |
Why?
| | Brain | 2 | 2018 | 2792 | 0.130 |
Why?
| | Down-Regulation | 2 | 2016 | 635 | 0.130 |
Why?
| | Self Care | 1 | 2019 | 387 | 0.120 |
Why?
| | Time Factors | 5 | 2024 | 6851 | 0.120 |
Why?
| | Cerebrovascular Circulation | 1 | 2018 | 269 | 0.120 |
Why?
| | Histone Deacetylases | 1 | 2018 | 209 | 0.120 |
Why?
| | Transition to Adult Care | 1 | 2017 | 89 | 0.120 |
Why?
| | Polypharmacy | 1 | 2017 | 88 | 0.120 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2018 | 259 | 0.120 |
Why?
| | Anesthetics | 1 | 2017 | 98 | 0.120 |
Why?
| | Eligibility Determination | 1 | 2016 | 68 | 0.120 |
Why?
| | Nonprescription Drugs | 1 | 2016 | 63 | 0.120 |
Why?
| | Cell Differentiation | 2 | 2021 | 1992 | 0.120 |
Why?
| | Prosthesis Design | 3 | 2014 | 333 | 0.120 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 2015 | 22 | 0.120 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1034 | 0.120 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2016 | 89 | 0.120 |
Why?
| | Drug Interactions | 1 | 2017 | 404 | 0.120 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 525 | 0.120 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2018 | 428 | 0.120 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 304 | 0.120 |
Why?
| | Antiviral Agents | 1 | 2021 | 735 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1746 | 0.110 |
Why?
| | Tacrolimus | 1 | 2016 | 192 | 0.110 |
Why?
| | Phosphorylation | 3 | 2019 | 1760 | 0.110 |
Why?
| | Postoperative Care | 1 | 2017 | 274 | 0.110 |
Why?
| | Hospital Mortality | 2 | 2009 | 918 | 0.110 |
Why?
| | Prescription Drugs | 1 | 2016 | 112 | 0.110 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1229 | 0.110 |
Why?
| | Viscosity | 1 | 2015 | 92 | 0.110 |
Why?
| | Partial Thromboplastin Time | 1 | 2014 | 53 | 0.110 |
Why?
| | Elastic Modulus | 1 | 2015 | 123 | 0.110 |
Why?
| | Cardiovascular Agents | 2 | 2020 | 156 | 0.110 |
Why?
| | Biomarkers | 3 | 2023 | 4092 | 0.110 |
Why?
| | Health Status | 1 | 2019 | 819 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2020 | 695 | 0.110 |
Why?
| | Hypoglycemic Agents | 1 | 2023 | 1341 | 0.110 |
Why?
| | Rats | 5 | 2022 | 5594 | 0.100 |
Why?
| | Systole | 1 | 2014 | 174 | 0.100 |
Why?
| | Atherosclerosis | 1 | 2018 | 401 | 0.100 |
Why?
| | Attitude to Health | 1 | 2017 | 457 | 0.100 |
Why?
| | Hip Prosthesis | 1 | 2014 | 46 | 0.100 |
Why?
| | Liver Transplantation | 1 | 2020 | 749 | 0.100 |
Why?
| | Shock, Cardiogenic | 1 | 2014 | 59 | 0.100 |
Why?
| | Incidence | 3 | 2019 | 2747 | 0.100 |
Why?
| | Patient Selection | 2 | 2017 | 676 | 0.100 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1470 | 0.100 |
Why?
| | Ambulatory Care | 1 | 2017 | 575 | 0.100 |
Why?
| | Vaccination | 1 | 2022 | 1437 | 0.100 |
Why?
| | Prosthesis Failure | 1 | 2014 | 123 | 0.100 |
Why?
| | Marijuana Smoking | 1 | 2016 | 261 | 0.100 |
Why?
| | Blood Coagulation | 1 | 2014 | 262 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1213 | 0.100 |
Why?
| | Patient Education as Topic | 1 | 2017 | 766 | 0.100 |
Why?
| | Mice, Knockout | 3 | 2025 | 3028 | 0.090 |
Why?
| | Young Adult | 6 | 2019 | 13305 | 0.090 |
Why?
| | Ventricular Premature Complexes | 1 | 2012 | 36 | 0.090 |
Why?
| | Nuclear Proteins | 1 | 2016 | 706 | 0.090 |
Why?
| | Natriuretic Peptides | 1 | 2011 | 9 | 0.090 |
Why?
| | Biopsy | 1 | 2015 | 1072 | 0.090 |
Why?
| | Attitude of Health Personnel | 2 | 2017 | 1157 | 0.090 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3307 | 0.090 |
Why?
| | Risk Factors | 4 | 2020 | 10252 | 0.080 |
Why?
| | Neurotransmitter Agents | 1 | 2011 | 81 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 2 | 2010 | 896 | 0.080 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2011 | 69 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2022 | 164 | 0.080 |
Why?
| | Gene Expression Regulation | 3 | 2020 | 2590 | 0.080 |
Why?
| | Connectin | 2 | 2022 | 35 | 0.080 |
Why?
| | Endpoint Determination | 2 | 2020 | 77 | 0.080 |
Why?
| | Decision Making | 1 | 2017 | 948 | 0.080 |
Why?
| | Stroke | 1 | 2019 | 1136 | 0.080 |
Why?
| | Task Performance and Analysis | 1 | 2011 | 191 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1941 | 0.080 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 196 | 0.080 |
Why?
| | Pericardial Effusion | 1 | 2010 | 21 | 0.080 |
Why?
| | Heart Septum | 1 | 2009 | 29 | 0.080 |
Why?
| | Extracellular Matrix Proteins | 1 | 2011 | 157 | 0.080 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2011 | 228 | 0.080 |
Why?
| | Anticoagulants | 1 | 2014 | 667 | 0.080 |
Why?
| | DNA | 1 | 2016 | 1438 | 0.080 |
Why?
| | Myocardial Revascularization | 1 | 2009 | 74 | 0.080 |
Why?
| | Comorbidity | 2 | 2020 | 1656 | 0.080 |
Why?
| | Cells, Cultured | 3 | 2022 | 4181 | 0.080 |
Why?
| | Exercise | 1 | 2020 | 2072 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1374 | 0.070 |
Why?
| | Ultrasonography | 1 | 2012 | 745 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2022 | 4315 | 0.070 |
Why?
| | Europe | 2 | 2020 | 407 | 0.070 |
Why?
| | Transcription Factors | 1 | 2016 | 1697 | 0.070 |
Why?
| | Coronary Circulation | 1 | 2008 | 136 | 0.070 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5798 | 0.070 |
Why?
| | Syndrome | 1 | 2008 | 377 | 0.070 |
Why?
| | Cardiac Catheterization | 2 | 2020 | 529 | 0.070 |
Why?
| | Blood Flow Velocity | 1 | 2008 | 411 | 0.060 |
Why?
| | Body Temperature | 1 | 2007 | 224 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 745 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2025 | 7677 | 0.060 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 281 | 0.060 |
Why?
| | Delivery of Health Care | 2 | 2023 | 958 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 3 | 2020 | 2339 | 0.060 |
Why?
| | Benzoic Acid | 1 | 2025 | 5 | 0.060 |
Why?
| | Survivors | 1 | 2009 | 498 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 403 | 0.060 |
Why?
| | Clinical Protocols | 2 | 2017 | 273 | 0.060 |
Why?
| | Benzoxazoles | 1 | 2024 | 19 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2009 | 1567 | 0.060 |
Why?
| | Education, Medical, Graduate | 1 | 2009 | 496 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2024 | 98 | 0.050 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2025 | 199 | 0.050 |
Why?
| | Genotype | 2 | 2020 | 1842 | 0.050 |
Why?
| | Sarcoplasmic Reticulum | 1 | 2023 | 43 | 0.050 |
Why?
| | Troponin | 1 | 2023 | 51 | 0.050 |
Why?
| | Administration, Oral | 1 | 2025 | 788 | 0.050 |
Why?
| | Cytokines | 1 | 2011 | 2080 | 0.050 |
Why?
| | Travel | 1 | 2023 | 134 | 0.050 |
Why?
| | Histone Deacetylase 6 | 1 | 2022 | 17 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2020 | 5520 | 0.050 |
Why?
| | Disulfides | 1 | 2022 | 97 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2022 | 150 | 0.050 |
Why?
| | Catecholamines | 1 | 2022 | 91 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1323 | 0.050 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2002 | 39 | 0.050 |
Why?
| | Up-Regulation | 1 | 2025 | 851 | 0.050 |
Why?
| | RNA Splicing Factors | 1 | 2022 | 56 | 0.050 |
Why?
| | Death, Sudden, Cardiac | 1 | 2023 | 188 | 0.050 |
Why?
| | Pyrazoles | 1 | 2025 | 425 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2018 | 2499 | 0.050 |
Why?
| | Calcium Channels | 1 | 2022 | 156 | 0.040 |
Why?
| | Signal Transduction | 3 | 2021 | 5086 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2022 | 310 | 0.040 |
Why?
| | Adolescent | 4 | 2019 | 21564 | 0.040 |
Why?
| | Valsalva Maneuver | 1 | 2021 | 9 | 0.040 |
Why?
| | Graft Survival | 1 | 2023 | 491 | 0.040 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2002 | 147 | 0.040 |
Why?
| | Anaerobic Threshold | 1 | 2021 | 28 | 0.040 |
Why?
| | Phenylephrine | 1 | 2021 | 75 | 0.040 |
Why?
| | Diagnostic Techniques, Cardiovascular | 1 | 2020 | 11 | 0.040 |
Why?
| | Prevalence | 2 | 2018 | 2727 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 60 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2022 | 395 | 0.040 |
Why?
| | Cardiomegaly | 1 | 2022 | 168 | 0.040 |
Why?
| | Culture Media | 1 | 2021 | 163 | 0.040 |
Why?
| | Chronic Disease | 2 | 2017 | 1805 | 0.040 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2021 | 122 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 1949 | 0.040 |
Why?
| | Survival Rate | 1 | 2025 | 1935 | 0.040 |
Why?
| | Heart Valve Diseases | 1 | 2002 | 153 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2023 | 728 | 0.040 |
Why?
| | Cytomegalovirus | 1 | 2021 | 161 | 0.040 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2020 | 40 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2020 | 56 | 0.040 |
Why?
| | Norepinephrine | 1 | 2021 | 192 | 0.040 |
Why?
| | Electric Countershock | 1 | 2020 | 106 | 0.040 |
Why?
| | Seizures | 1 | 2023 | 431 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2022 | 489 | 0.040 |
Why?
| | Acylation | 1 | 2019 | 31 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2023 | 310 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 624 | 0.040 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 68 | 0.040 |
Why?
| | Program Evaluation | 2 | 2017 | 916 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2020 | 102 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 196 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 193 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2022 | 462 | 0.040 |
Why?
| | Methylation | 1 | 2019 | 227 | 0.040 |
Why?
| | Internship and Residency | 1 | 2009 | 1187 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 315 | 0.040 |
Why?
| | Mice, Knockout, ApoE | 1 | 2018 | 11 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2020 | 517 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 349 | 0.040 |
Why?
| | Fatty Acids | 1 | 2021 | 444 | 0.030 |
Why?
| | Hydroxamic Acids | 1 | 2018 | 90 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2021 | 710 | 0.030 |
Why?
| | Fibroblasts | 1 | 2022 | 1003 | 0.030 |
Why?
| | Zebrafish | 1 | 2022 | 496 | 0.030 |
Why?
| | Hyperplasia | 1 | 2018 | 176 | 0.030 |
Why?
| | Lysine | 1 | 2019 | 290 | 0.030 |
Why?
| | Myosins | 1 | 2018 | 137 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 459 | 0.030 |
Why?
| | Autoradiography | 1 | 2017 | 69 | 0.030 |
Why?
| | Fluorine Radioisotopes | 1 | 2017 | 13 | 0.030 |
Why?
| | Alleles | 1 | 2020 | 887 | 0.030 |
Why?
| | Diphenoxylate | 1 | 2016 | 5 | 0.030 |
Why?
| | Antidiarrheals | 1 | 2016 | 14 | 0.030 |
Why?
| | Loperamide | 1 | 2016 | 12 | 0.030 |
Why?
| | Atropine | 1 | 2016 | 36 | 0.030 |
Why?
| | Papio | 1 | 2017 | 94 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 416 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 398 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 5803 | 0.030 |
Why?
| | Organ Culture Techniques | 1 | 2017 | 157 | 0.030 |
Why?
| | Tissue Donors | 1 | 2019 | 395 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2020 | 421 | 0.030 |
Why?
| | Transcription Elongation, Genetic | 1 | 2016 | 23 | 0.030 |
Why?
| | Transcription Initiation Site | 1 | 2016 | 43 | 0.030 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2018 | 209 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2017 | 185 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2016 | 67 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 622 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2021 | 873 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2016 | 145 | 0.030 |
Why?
| | Actins | 1 | 2018 | 419 | 0.030 |
Why?
| | Acetylation | 1 | 2016 | 244 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 346 | 0.030 |
Why?
| | Circadian Rhythm | 1 | 2020 | 489 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 793 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2018 | 819 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1309 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2018 | 450 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2876 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 3637 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 980 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2030 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 540 | 0.030 |
Why?
| | Factor X | 1 | 2014 | 27 | 0.030 |
Why?
| | Self-Management | 1 | 2017 | 192 | 0.030 |
Why?
| | Mental Health | 1 | 2021 | 738 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2172 | 0.030 |
Why?
| | Cobalt | 1 | 2014 | 51 | 0.030 |
Why?
| | Action Potentials | 1 | 2017 | 485 | 0.030 |
Why?
| | Reoperation | 1 | 2016 | 579 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1047 | 0.030 |
Why?
| | Warfarin | 1 | 2014 | 153 | 0.030 |
Why?
| | Models, Biological | 1 | 2021 | 1806 | 0.030 |
Why?
| | Amino Acids, Aromatic | 1 | 2013 | 8 | 0.030 |
Why?
| | Self Report | 1 | 2017 | 839 | 0.020 |
Why?
| | RNA Polymerase II | 1 | 2016 | 325 | 0.020 |
Why?
| | Proteomics | 1 | 2019 | 1110 | 0.020 |
Why?
| | Heparin | 1 | 2014 | 258 | 0.020 |
Why?
| | Medication Adherence | 1 | 2017 | 504 | 0.020 |
Why?
| | Creatine | 1 | 2013 | 62 | 0.020 |
Why?
| | Child, Preschool | 2 | 2019 | 11158 | 0.020 |
Why?
| | Mass Screening | 1 | 2021 | 1292 | 0.020 |
Why?
| | Glutamine | 1 | 2013 | 103 | 0.020 |
Why?
| | Antibodies | 1 | 2014 | 404 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1740 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 616 | 0.020 |
Why?
| | Alanine | 1 | 2013 | 152 | 0.020 |
Why?
| | Chromatin | 1 | 2016 | 515 | 0.020 |
Why?
| | Dyspnea | 1 | 2014 | 255 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2020 | 2815 | 0.020 |
Why?
| | Fatigue | 1 | 2014 | 336 | 0.020 |
Why?
| | Depression | 1 | 2021 | 1466 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 935 | 0.020 |
Why?
| | Lactic Acid | 1 | 2013 | 303 | 0.020 |
Why?
| | Phenotype | 1 | 2020 | 3139 | 0.020 |
Why?
| | Patient Discharge | 1 | 2016 | 916 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 2044 | 0.020 |
Why?
| | Catheter Ablation | 1 | 2012 | 302 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 3256 | 0.020 |
Why?
| | Child | 2 | 2019 | 21921 | 0.020 |
Why?
| | Glucose | 1 | 2013 | 1032 | 0.020 |
Why?
| | Focus Groups | 1 | 2009 | 539 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2009 | 741 | 0.010 |
Why?
| | Infant | 1 | 2015 | 9574 | 0.010 |
Why?
| | Clinical Competence | 1 | 2009 | 1149 | 0.010 |
Why?
| | Observer Variation | 1 | 2002 | 350 | 0.010 |
Why?
|
|
Ambardekar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|